Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: Results of a randomized, double-blind, placebo-controlled trial

Critical Care Medicine

Volumn 34, Issue 6, 2006, Pages 1661-1667

  Vincent, Jean Louis ^a   Spapen, Herbert D M H ^b   Creteur, Jacques ^a   Piagnerelli, Michael ^a   Hubloue, Ives ^b   Diltoer, Marc ^b   Roman, Alain ^c   Stevens, Etienne ^c   Vercammen, Els ^d   Beaver, Jessica S ^d  

^a ERASME HOSPITAL   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^c SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^d JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Anemia; Erythropoietin; Hemoglobin; Pharmacodynamics; Pharmacokinetics; Transfusion

Indexed keywords

ERYTHROPOIETIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BLOOD SAMPLING; BLOOD TRANSFUSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE COUNT; FEMALE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOKALEMIA; MALE; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE; SEPSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; CRITICAL ILLNESS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EPOETIN ALFA; ERYTHROCYTE COUNT; ERYTHROPOIETIN; FEMALE; FOLLOW-UP STUDIES; HEMATINICS; HEMOGLOBINS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33744546570     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000217919.22155.85     Document Type: Article

References (17)

1. Corwin HL, Krantz SB: Anemia of the critically ill: "Acute" anemia of chronic disease. Crit Care Med 2000; 28:3098-3099
2. Corwin HL, Gettinger A, Pearl RG, et al: The CRIT Study: Anemia and blood transfusion in the critically ill. Current clinical practice in the United States. Crit Care Med 2004; 32:39-52
3. Vincent JL, Baron JF, Reinhart K, et al: Anemia and blood transfusion in critically ill patients. JAMA 2002; 288:1499-1507
4. von Ahsen N, Muller C, Serke S, et al: Important role of nondiagnostic blood loss and blunted erythropoietic response in the anemia of medical intensive care patients. Crit Care Med 1999; 27:2630-2639
5. Rogiers P, Zhang H, Leeman M, et al: Erythropoietin response is blunted in critically ill patients. Intensive Care Med 1997; 23:159-162
6. Rodriguez RM, Corwin HL, Gettinger A, et al: Nutritional deficiencies and blunted erythropoietin response as causes of the anemia of critical illness. J Crit Care 2001; 16:36-41
7. van Iperen CE, Gaillard CA, Kraaijenhagen RJ, et al: Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients. Crit Care Med 2000; 28:2773-2778
8. Corwin HL, Gettinger A, Rodriguez RM, et al: Efficacy of recombinant human erythropoietin in the critically ill patient: A randomized, double-blind, placebo-controlled trial. Crit Care Med 1999; 27:2346-2350
9. Corwin HL, Gettinger A, Pearl RG, et al: Efficacy of recombinant human erythropoietin in critically ill patients: A randomized controlled trial. JAMA 2002; 288:2827-2835
10. Glaspy J, Bukowski R, Steinberg D, et al: Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997; 15:1218-1234
11. Demetri GD, Kris M, Wade J, et al: Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998; 16:3412-3425
12. Littlewood TJ, Bajetta E, Nortier JW, et al: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19:2865-2874
13. Cheung WK, Goon BL, Guilfoyle MC, et al: Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects. Clin Pharmacol Ther 1998; 64:412-423
14. Cheung W, Minton N, Gunawardena K: Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly. Eur J Clin Pharmacol 2001; 57:411-418
15. Gabrilove JL, Cleeland CS, Livingston RB, et al: Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19:2875-2882
16. Vincent JL, de Mendonça A, Cantraine F, et al: Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: Results of a multicentric, prospective study. Crit Care Med 1998; 26:1793-1800
17. McMahon FG, Vargas R, Ryan M, et al: Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood 1990; 76:1718-1722